反応式
[C:1]([O:5][C:6]([N:8]1[CH:17]([CH3:18])[CH2:16][C:15]2[C:14]([O:19][C:20]3[CH:21]=[C:22]4[C:26](=[CH:27][CH:28]=3)[NH:25][CH:24]=[CH:23]4)=[N:13][CH:12]=[N:11][C:10]=2[CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].C1N=CN([C:34]([N:36]2[CH:40]=[N:39]C=C2)=[O:35])C=1.[C:41]([C:45]1[CH:46]=C(N)N[N:49]=1)([CH3:44])([CH3:43])[CH3:42].N1(C2C=CN=CC=2)CCCC1>CN(C=O)C>[C:1]([O:5][C:6]([N:8]1[CH:17]([CH3:18])[CH2:16][C:15]2[C:14]([O:19][C:20]3[CH:21]=[C:22]4[C:26](=[CH:27][CH:28]=3)[N:25]([C:34](=[O:35])[NH:36][C:40]3[NH:39][N:49]=[C:45]([C:41]([CH3:44])([CH3:43])[CH3:42])[CH:46]=3)[CH:24]=[CH:23]4)=[N:13][CH:12]=[N:11][C:10]=2[CH2:9]1)=[O:7])([CH3:2])([CH3:3])[CH3:4]参加物
6
実験手順
A solution of 4-(1H-indol-5-yloxy)-6-methyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid tert-butyl ester (210 mg, 0.55 mmol), CDI (179 mg, 1.10 mmol), TEA (230 uL, 1.65 mmol), and DMF (5 mL) is stirred at rt 1 h before 5-tert-butyl-2H-pyrazol-3-ylamine (77 mg, 0.55 mmol) and 4-pyrrolidinopyridine (16.4 mg, 0.11 mmol) are added. After 24 h, the reaction is concentrated in vacuo and the purified via FCC (5-90% EtOAc/heptane) to give the title compound. MS (ESI) m/z 546.3 (M+1).
後処理
- additionare added
- concentrationthe reaction is concentrated in vacuo
- customthe purified via FCC (5-90% EtOAc/heptane)
出典と根拠
- ORDレコード
- ord-6041192d631e4d2a93872cd1b8b0f3a0
- 出典データセット
- uspto-grants-2013_07
- 特許番号
- US08486954B2
関連ノート
読み込み中…